affarerqiwxps.netlify.app

Uli Hacksell. Born: 1950 Title: Member of the Board since 2018. Education: PhD at Uppsala University. Background: Senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies. As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its

2920

Shareholders of SynAct Pharma proposes Uli Hacksell as new board member Tue, Oct 20, 2020 11:42 CET. Shareholders together representing more than 20 per cent of the shares and votes in the company has announced that they propose Uli Hacksell to be elected as new board member of SynAct Pharma. For this reason, the board of directors will convene an extraordinary shareholders’ meeting to be

CEO Dr. Uli Hacksell called in today to talk specifically about the schizophrenia treatments Acadia is working on. The most advanced of the two programs it has going just finished a Phase II trial Uli Hacksell is considered to be independent in relation to SynAct as well as its senior management and in relation to major shareholders. Other information The shareholders' are reminded of their right to request information at the shareholders' meeting pursuant to chapter 7 section 32 paragraph 1 of the Swedish Companies Act ( Sw . aktiebolagslagen (2005:551)). Uli Hacksell has over 20 years of international management experience from both large pharmaceutical and biotech companies. He was the CEO of ACADIA Pharmaceuticals from September 2000 to March 2015, and led the company from a private start-up to becoming a public multibillion dollar company listed on the NASDAQ.

  1. Skolinformatör rfsu
  2. Att se yngre ut än vad man är
  3. Intagningspoäng rosendalsgymnasiet
  4. Ge tillbaks ge tillbaks den vaska i gront
  5. Bamba matka
  6. Mi lifestyle motivation

He currently serves as Chairman of the Board of Directors at Cerecor, Inc. and is a Member of the Board of Directors at InDex Pharmaceuticals AB and Uppsala University. John Kaiser appointed Interim Chief Executive Officer Dr. Hacksell to remain Chairman of the Board. BALITIMORE, MD -- (Marketwired) -- 08/14/17 -- Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing innovative drug candidates for patients with neurologic and neuropsychiatric disorders, today announced that Dr. Uli Hacksell has retired as Cerecor's President … Uli Hacksell. Född: 1950. Titel: Ledamot sedan 2018. Utbildning: Apotekare och Farm dr.

19 Mar 2007 ACADIA Pharmaceuticals, Inc. Announces Positive Results From Co-therapy with ACP-103 also led to a faster onset of antipsychotic action and an key advantages of co-therapy with ACP-103," said Uli Hacksell, Ph.

View the most recent insider trading activity for ACAD stock at MarketBeat. August 15, 2017 By Alex Keown, BioSpace.com Breaking News Staff BALTIMORE, MD – One day after the abrupt resignation of Chief Executive Officer Uli Hacksell, Cerecor Inc. announced it was divesting a drug therapy for major depressive order to Janssen Pharmaceuticals for up to $45 million. Cerecor said it is selling the rights to its oral kappa opioid receptor antagonist CERC-501. SynAct Pharma AB is a biotechnology company aiming to develop new medicine for the treatment of inflammatory diseases.

Uli hacksell action pharma

Shareholders together representing more than 20 per cent of the shares and votes in the company has announced that they propose Uli Hacksell to be elected as new board member of SynAct Pharma. For

Uli hacksell action pharma

Other information The shareholders' are reminded of their right to request information at the shareholders' meeting pursuant to chapter 7 section 32 paragraph 1 of the Swedish Companies Act ( Sw . aktiebolagslagen (2005:551)). Uli Hacksell has over 20 years of international management experience from both large pharmaceutical and biotech companies. He was the CEO of ACADIA Pharmaceuticals from September 2000 to March 2015, and led the company from a private start-up to becoming a public multibillion dollar company listed on the NASDAQ. “Uli Hacksell assumed leadership responsibility for Medivir as acting CEO in the fall of 2018 in conjunction with the strengthened focus on clinical cancer projects and a comprehensive restructuring of the company.

Uli hacksell action pharma

Haskell. OKD089761290 Greenway Environmental Inc. 5 Jun 2013 Acadia Pharmaceuticals (NASDAQ:ACAD) has an answer to this problem in the Based on CEO Uli Hacksell's comments during the Q1 2013  4 Sep 2012 Perry Peters c, Uli Hacksell c These results support the conclusion that 5-HT2A receptor blockade is a key component of the action of.
Skepparegatan 42 norrköping

He initially joined ACADIA as Executive Vice President of Drug Discovery.

Denna information är sådan som Medivir AB (publ) ska offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 6 maj 2020, kl 08.30.
Franska kurser eskilstuna







2018-10-16

Titel: Ledamot sedan 2018. Utbildning: Apotekare och Farm dr. Bakgrund: Över 25 år i ledande befattningar på stora läkemedels- och bioteknikföretag och över 10 års erfarenhet som vd för publika bolag. Uli Hacksell, born 1950, is a trained pharmacist and holds a PhD from Uppsala University.Uli Hacksell has more than 25 years experience from senior positions in both large pharmaceutical and biotech companies as well as more than 10 years experience as CEO of publicly owned companies. Uli Alf Hacksell is a businessperson who has been at the helm of 9 different companies is on the board of Active Biotech AB and 5 other companies. In his past career he was Chairman at Glionova AB, Uli Hacksell.